Disease Domain | Count |
---|---|
Nervous System Diseases | 6 |
Endocrinology and Metabolic Disease | 5 |
Immune System Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Oligonucleotide | 2 |
Chemical drugs | 1 |
ASO | 1 |
Synthetic peptide | 1 |
Target |
Mechanism BAX modulators [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc. Canada |
First Approval Date10 Jun 2022 |
Target |
Mechanism GLP-1R antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CAPN2 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date29 Apr 2025 |
Sponsor / Collaborator |
Start Date07 Apr 2025 |
Sponsor / Collaborator |
Start Date21 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Sodium Phenylbutyrate/Tauroursodeoxycholic Acid ( BAX x HDACs ) | Amyotrophic Lateral Sclerosis More | Phase 3 |
Avexitide ( GLP-1R ) | Congenital Hyperinsulinism More | Phase 2 |
AMX-0114 ( CAPN2 ) | Amyotrophic Lateral Sclerosis More | Phase 1 |
AKT/PI3K/mTOR inhibitors(Thryv Therapeutics) ( Akt x PI3Kγ x mTOR ) | Dementia More | Preclinical |
Long-Acting GLP-1 Receptor Antagonist(Amylyx Pharmaceuticals) ( GLP-1R ) | Hypoglycemia More | Preclinical |